| Schedule of Basic and Diluted Net Loss Per Share |
The components of basic and diluted net income (loss) per share were as follows: | | | Three months ended June 30, | | | Six months ended June 30, | | | (In thousands, except share and per share data) | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Numerator: | | | | | | | | | | | | | | Net income (loss) from continuing operations | | $ | 1,184 | | | $ | (7,205 | ) | | $ | 21,106 | | | $ | (10,479 | ) | | Net (loss) income from discontinued operations | | | — | | | | (155 | ) | | | — | | | | 1,493 | | | Minus: net income allocated to participating warrants | | | (990 | ) | | | — | | | | (17,638 | ) | | | — | | | Numerator for basic EPS - Net income (loss) available for common shareholders | | $ | 194 | | | $ | (7,360 | ) | | $ | 3,468 | | | $ | (8,986 | ) | | | | | | | | | | | | | | | | | | | | Effect of dilutive securities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Interest expense on Convertible Notes - from continuing operations | | $ | — | | | $ | — | | | $ | 2,960 | | | $ | — | | | Reallocation of net income to participating warrants | | | 10 | | | | — | | | | 1,397 | | | | — | | | Numerator for diluted EPS - Net income (loss) available for common shareholders | | $ | 204 | | | $ | (7,360 | ) | | $ | 7,825 | | | $ | (8,986 | ) | | | | | | | | | | | | | | | | | | | | Denominator: | | | | | | | | | | | | | | | | | | Denominator for basic EPS - Weighted-average common shares outstanding | | | 2,155,721 | | | | 1,965,425 | | | | 2,152,443 | | | | 1,958,724 | | | Effect of dilutive securities | | | | | | | | | | | | | | | | | | Unvested restricted stock units | | | 128,250 | | | | — | | | | 128,250 | | | | — | | | Conversion of Convertible Notes | | | — | | | | — | | | | 2,971,433 | | | | — | | | Denominator for diluted EPS - adjusted weighted-average common stock outstanding | | | 2,283,971 | | | | 1,965,425 | | | | 5,252,126 | | | | 1,958,724 | | | Basic net income (loss) per share attributable to common shareholders | | $ | 0.09 | | | $ | (3.74 | ) | | $ | 1.61 | | | $ | (4.59 | ) | | Diluted net income (loss) per share attributable to common shareholders | | $ | 0.09 | | | $ | (3.74 | ) | | $ | 1.49 | | | $ | (4.59 | ) |
|
| Schedule of Anti-Dilutive Shares |
The Company’s pre-funded warrants are considered participating securities and are reflected through the application of the two-class method; accordingly, they are not included in the diluted earnings per share denominator in periods in which the two-class method results in the most dilutive outcome. | | | Six months ended June 30, | | | | | 2026 | | | 2025 | | | Shares subject to outstanding warrants | | | 11,034,325 | | | | 7,595,187 | | | Shares subject to unvested restricted stock units | | | — | | | | 80,000 | | | Shares subject to outstanding stock options | | | 75 | | | | 75 | | | | | | 11,034,400 | | | | 7,675,262 | |
|